October 22, 2026 · Gastroenterology · DOI: 10.1053/j.gastro.2026.09.027

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.

Listen to this summary

The authors investigate the metabolic adaptations that occur in pancreatic ductal adenocarcinoma (PDAC) cells following acquired resistance to gemcitabine, aiming to identify potential therapeutic vulnerabilities. They find that gemcitabine-resistant cells exhibit a dependency on the mevalonate biosynthesis pathway, making them sensitive to statin treatment, and suggest that HMGCR expression could serve as a biomarker for predicting treatment response in PDAC patients.

Alica K Michels, Sabrina Calderon, Ethan Nghiem, Eleni Zimmer, Leonor Schubert Santana, Rima Singh, Tim Eiseler, Chantal Allgöwer, Gregory Tong, Sharon Wu, Kevin Gulay, Mumina Sadullozoda, Austin Silva, Cecily Anaraki, Natalie Yousefian, Devon F Pendlebury, Cameron Geller, Alina Chao, Dennis Juarez, Thomas Seufferlein, Cholsoon Jang, Aimee L Edinger, Marcus Seldin, Alexander Muir, Thomas F Martinez, Alexander Kleger, David K Chang, Herve Tiriac, Jennifer B Valerin, David A Fruman, Christopher J Halbrook

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play